NuvOx Therapeutics
Tucson, US · Founded 2022 · Delaware corporation
NuvOx Therapeutics is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen flow from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radio sensitizer), stroke, and respiratory distress.
Founders & leadership
NuvOx Therapeutics was founded in 2022 by Evan Unger.
EU
Evan UngerFounder
RW
Rong WangExecutive
JJ
Jennifer JohnsonExecutive
MS
Marvin SlepianNamed on SEC filing
JS
Jonathan SchillingNamed on SEC filing
Board
MJ
Marvin J. SlepianBoard director
RC
Richard CarmonaBoard director
JT
Jonathan T. SchillingBoard director
JS
Jon SaxeBoard director
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 2 rounds · 2023–2024
▶$235KraisedNov 2024 · 4 investors · PharmaceuticalsRule 506(b)
▶$235KraisedNov 2024 · 4 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Marvin J. SlepianDirector
- Richard CarmonaDirector
- Jonathan T. SchillingDirector
- Jon SaxeDirector
- Rong WangExecutive Officer
- Evan UngerExecutive Officer, Director
- Jennifer JohnsonExecutive Officer
- Offering amount
- $7M
- Amount sold
- $235K
- Minimum investment
- $35K
- Sales commissions
- $405.9K
- Placement agents
- Donald Capital, LLC
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
▶$1.1MraisedFeb 2023 · 2 investors · Other Health CareRule 506(b)
▶$1.1MraisedFeb 2023 · 2 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jon SaxeDirector
- Marvin SlepianDirector
- Richard CarmonaDirector
- Rong WangExecutive Officer
- Evan C UngerExecutive Officer, Director
- Jonathan SchillingDirector
- Offering amount
- $5M
- Amount sold
- $1.1M
- Minimum investment
- $50K
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware, 2022
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapRenovo Rx8 shared keywordsRenovoRx develops targeted oncology therapies and commercializes the RenovoCath, an FDA-cleared drug-delivery device for intra-arterial chemotherapy administration in cancer treatment. The company is conducting Phase III clinical trials of its proprietary TAMP therapy platform for treating locally advanced pancreatic cancer with improved safety and efficacy compared to systemic chemotherapy.
Medscape7 shared keywordsMedscape is an online medical information platform providing clinical news, expert perspectives, case studies, quizzes, and reference material across specialties such as cardiology, oncology, neurology, and psychiatry. It serves physicians, nurses, pharmacists, residents, and medical students.
Nuvalent7 shared keywords
Companies competing with NuvOx Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does NuvOx Therapeutics do?
- NuvOx Therapeutics is a clinical-stage pharmaceutical company developing NanO₂, an oxygen therapeutic drug intended to improve oxygen flow from lungs to blood and to tissue in order to reverse tissue hypoxia. Its clinical programs target indications including glioblastoma (as a radio sensitizer), stroke, and respiratory distress.
- Who founded NuvOx Therapeutics?
- NuvOx Therapeutics was founded by Evan Unger in 2022.
- How much funding has NuvOx Therapeutics raised?
- NuvOx Therapeutics has disclosed $1.3M raised across 2 rounds.
- Where is NuvOx Therapeutics headquartered?
- NuvOx Therapeutics is headquartered in Tucson, US.